Clin2
NCT05838287Possibly a fitRecruiting

Pioglitazone for heart failure with preserved pumping in type 2 diabetes

Type 2 Diabetes Mellitus in ObeseHeart Failure With Preserved Ejection Fraction

Treatments studied

Part of Heart & circulation, Hormones & metabolism clinical trials.

This trial tests whether pioglitazone (a diabetes medicine) helps people who have type 2 diabetes and a specific type of heart failure where the heart pumps normally. It may improve heart failure symptoms and function in carefully selected patients.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
78 people
Ages
30 years to 70 years
Study type
Interventional

Who can take part

  • You can sign a consent form and can follow the study for its full duration
  • You’re age 30 to 70 and your BMI is 27.5 to 40
  • Your type 2 diabetes labs (HbA1c) are between 6.5 and 10
  • Your kidney function is adequate (eGFR above 45), and your blood pressure is not over 145/65
  • You have HFpEF (heart failure with preserved pumping, ejection fraction over 50%) and NYHA class II to III heart symptoms
  • You are on an approved diabetes treatment (diet/exercise, metformin, sulfonylurea, metformin+SU, DPP-4 inhibitor, or insulin)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05057806Recruiting· Early Phase 1
Testing how ketones may affect heart benefits in type 2 diabetes

This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.

San Antonio, Texas
NCT06510270Not yet recruiting
Dapagliflozin for heart failure with preserved pumping strength

This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.

NCT07787936Not yet recruiting
New diabetes-like drugs for heart failure with obesity

This study is testing whether a new class of medications, known as GLP-1/GIP receptor agonists, can help improve symptoms and heart health in people who have heart failure with preserved ejection fraction and are overweight or obese. It is a registry that tracks participants' health over time to learn about the treatment's effects.

Lubin, Lower Silesian Voivodeship
NCT06229678Recruiting· Early Phase 1
Ketones and diabetes drug for heart failure with weak pump

This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.

San Antonio, Texas
NCT07053319Recruiting· Phase 1
Study of diabetes drugs and ketones

This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.

San Antonio, Texas
NCT07288749Not yet recruiting· Phase 3
Glimepiride for type 2 diabetes and heart failure

This study tests whether a diabetes medication called glimepiride can help people who have both type 2 diabetes and heart failure with reduced pumping ability. It may improve heart failure symptoms and blood sugar control.

Wuhan, Hubei

Hear when a new Type 2 Diabetes Mellitus in Obese trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.